Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml

Abstract

Objectives: To determine the outcome of patients with a serum prostate-specific antigen (PSA) level >20 ng/ml that underwent radical prostatectomy (RP).

Methods: We retrospectively reviewed the medical records of 147 patients who underwent RP for clinically localized prostate cancer with a pre-treatment PSA (PSApt) >20 ng/ml. Fifty-two patients had positive pelvic lymph nodes and were excluded from analysis. Of 95 patients remaining, 15 were lost to follow-up. Therefore, the study group included 80 patients. The end points for this analysis were biochemical relapse-free survival (bRFS), surgical and post-operative complications and urinary continence. PSApt, pathological grade, surgical margin status, age, clinical stage and immediate androgen ablation were evaluated in a multivariate analysis regarding bRFS.

Results: Forty-nine resected specimens (61.2%) were pathologically classified as pT3 or pT4. After a mean follow-up of 64 months, the estimated 5-year bRFS rate was 58% for the overall group. Immediate androgen ablation was the only independent prognostic factor for biochemical relapse (P=0.001). Concerning the 21 patients who received an immediate androgen ablation after RP, the estimated 5-year bRFS rate was 92%. Complete urinary continence was achieved in 76.5% of patients. Early complications occurred in 13 patients (16.2%).

Conclusions: Clinically localized prostate cancer with a PSApt >20 ng/ml is considered as having a poor prognosis. However, RP performed in these patients led to an acceptable morbidity and good functional results. Immediate adjuvant hormonal therapy seems mandatory in this setting to improve bRFS.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Bostwick DG, Qian J, Bergstrahl E . Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996; 155: 1361–1367.

    Article  CAS  Google Scholar 

  2. Partin AW, Yoo J, Carter B, Pearson JD, Chan DW, Epstein JI et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150: 110–114.

    Article  CAS  Google Scholar 

  3. Kupelian PA, Katcher J, Levin HS, Klein EA . Stage T1–2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys 1997; 37: 1043–1052.

    Article  CAS  Google Scholar 

  4. D'Amico AV, Cote K, Loffredo M, Renshaw AA, Chen MH . Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 2003; 169: 1320–1324.

    Article  Google Scholar 

  5. D'Amico AV, Whittington R, Malkowicz SB, Weinstein M, Tomaszewski JE, Schultz D et al. Predicting prostate specific antigen outcome preoperatively in the prostate specific antigen era. J Urol 2001; 166: 2185–2188.

    Article  CAS  Google Scholar 

  6. Zagars GK, Pollack A, von Eschenbach AC . Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer 1997; 80: 764–775.

    Article  CAS  Google Scholar 

  7. Partin AW, Mohler JL, Piantadosi S, Brendler CB, Sanda MG, Walsh PC et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995; 45: 831–838.

    Article  CAS  Google Scholar 

  8. Anderson PR, Hanlon AL, Movsas B, Hanks GE . Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation. Int J Radiat Oncol Biol Phys 1997; 39: 1025–1030.

    Article  CAS  Google Scholar 

  9. Kupelian P, Katcher J, Levin H, Zippe C, Klein E . Correlation of clinical and pathological factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996; 48: 249–260.

    Article  CAS  Google Scholar 

  10. Freedland SJ, Sutter ME, Dorey F, Aronson WJ . Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology 2003; 61: 365–369.

    Article  Google Scholar 

  11. Hautmann RE, Sauter TW, Wenderoth UK . Radical retropubic prostatectomy: morbidity and urinary continence in 418 consecutive cases. Urology 1994; 43: 47–51.

    Article  CAS  Google Scholar 

  12. Stein A, deKernion JB, Smith RB, Dorey F, Patel H . Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 1992; 147: 942–946.

    Article  CAS  Google Scholar 

  13. Ritchie AW, James K, deKernion JB . Early post-operative morbidity of total prostatectomy. Br J Urol 1989; 64: 511–515.

    Article  CAS  Google Scholar 

  14. Leandri P, Rossignol G, Gautier JR, Ramon J . Radical retropubic prostatectomy : morbidity and quality of life. Experience with 620 consecutive cases. J Urol 1992; 147: 883–887.

    Article  CAS  Google Scholar 

  15. Catalona WJ, Carvalhal GF, Mager DE, Smith DS . Potency, continence and complications rates in 1870 consecutive radical retropubic prostatectomies. J Urol 1999; 162: 433–438.

    Article  CAS  Google Scholar 

  16. Donellan SM, Duncan HJ, MacGregor RJ, Russell JM . Prospective assessment of incontinence after radical retropubic prostatectomy: objective and subjective analysis. Urology 1997; 49: 225–230.

    Article  Google Scholar 

  17. Walsh PC . Radical prostatectomy for localized prostate cancer provides durable cancer control with excellent quality of life: a structured debate. J Urol 2000; 163: 1802–1807.

    Article  CAS  Google Scholar 

  18. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995; 154: 131–138.

    Article  CAS  Google Scholar 

  19. Brandli DW, Koch MO, Foster RS, Bihrle R, Gardner TA . Biochemical disease-free survival in patients with a high prostate-specific antigen level (20–100 ng/ml) and clinically localized prostate cancer after radical prostatectomy. BJU Int 2003; 92: 19–23.

    Article  CAS  Google Scholar 

  20. Cheng L, Slezak J, Bergstralh EJ, Myers RP, Zincke H, Bostwick DG . Preoperative prediction of surgical margin status in patients with prostate cancer treated by radical prostatectomy. J Clin Oncol 2000; 18: 2862–2868.

    Article  CAS  Google Scholar 

  21. Vanasupa BP, Paquette EL, Wu H, Sun L, McLeod DG, Moul JW . The role of radical prostatectomy in patients with pretreatment prostate-specific antigen 40 ng/ml. Urol Oncol 2002; 7: 167–172.

    Article  Google Scholar 

  22. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K et al. Bicalutamide 150 mg in addition to standard care in patients with localized orlocally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172: 1865–1870.

    Article  CAS  Google Scholar 

  23. Collette L, van Poppel H, Bolla M, van Cangh P, Vekemans K, Da Pozzo L et al. Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). Eur J Cancer 2005; 41: 2662–2672.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C Bastide.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bastide, C., Kuefer, R., Loeffler, M. et al. The role of radical prostatectomy in patients with clinically localized prostate cancer and a prostate-specific antigen level >20 ng/ml. Prostate Cancer Prostatic Dis 9, 239–244 (2006). https://doi.org/10.1038/sj.pcan.4500892

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500892

Keywords

This article is cited by

Search

Quick links